Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
Open accessThe DOI matches its Crossref record; 87 of the 89 references it cites were found in a registry or an index.
Abstract
Omega-3 fatty acid products are available as prescription formulations (icosapent ethyl, omega-3-acid ethyl esters, omega-3-acid ethyl esters A, omega-3-carboxylic acids) and dietary supplements (predominantly fish oils). Most dietary supplements and all but one prescription formulation contain mixtures of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Products containing both EPA and DHA may raise low-density lipoprotein cholesterol (LDL-C). In clinical trials, the EPA-only prescription product, icosapent ethyl, did not raise LDL-C compared with placebo. To correct a common misconception, it is important to note that omega-3 fatty acid dietary supplements are not US FDA-approved over-the-counter drugs and are not required to demonstrate safety and efficacy prior to marketing. Conversely, prescription products are supported by extensive clinical safety and efficacy investigations required for FDA approval and have active and ongoing safety monitoring programs. While omega-3 fatty acid dietary supplements may have a place in the supplementation of diet, they generally contain lower levels of EPA and DHA than prescription products and are not approved or intended to treat disease. Perhaps due to the lack of regulation of dietary supplements, EPA and DHA levels may vary widely within and between brands, and products may also contain unwanted cholesterol or fats or potentially harmful components, including toxins and oxidized fatty acids. Accordingly, omega-3 fatty acid dietary supplements should not be substituted for prescription products. Similarly, prescription products containing DHA and EPA should not be substituted for the EPA-only prescription product, as DHA may raise LDL-C and thereby complicate the management of patients with dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Structures of omega-3 fatty acids. Both omega-6 and omega-3 fatty acids are polyunsaturated fatty acids, meaning that the hydrocarbon chain contains multiple double bonds. The naming convention is [number of carbon atoms]:[number of double bonds], n- (or ω)-[position of first double bond starting from the methyl end of the chain, shown in red]. Omega-3 fatty acids generally have anti-inflammatory and anti-thrombotic properties, whereas omega-6 fatty acids generally have pro-inflammatory and pro-thrombotic properties](https://figures.cochat.ai/paper-figures/fa4fb9abe67a4a29bd4d25a9f0665aea/omega-3-fatty-acid-formulations-in-cardiovascular-disease-dietary-supplements-figure-1.jpg)

![Fig. 3 Percentage change from baseline versus placebo in key lipid parameters from clinical trials of prescription omega-3 fatty acid products (4 g/day) in patients with very high triglycerides (≥500 mg/dl) [48–50, 54]. Upper limit for triglycerides was 2000 mg/dl in studies of omega-3-acid ethyl esters, omega-3-carboxylic acids, and icosapent ethyl and 1500 mg in the omega-3-acid ethyl esters A study. Omega-3-acid ethyl esters values are based on pooled data from two studies [10, 11] (6 and 16 weeks’ duration) as reported in the omega-3-acid ethyl esters prescribing information [48]. Icosapent ethyl data are from the MARINE (Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension) study (12 weeks) [12]. Omega-3-acid ethyl esters A data (12 weeks) have only been published in the product’s prescribing information [49]. Omega-3-carboxylic acids data are from the EVOLVE (Epanova for Lowering Very High Triglycerides) study (12 weeks) [13]. Difference versus placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change—placebo median % change; icosapent ethyl = median of [icosapent ethyl % change—placebo % change] (Hodges–Lehmann estimate); omega-3-acid ethyl esters A = Hodges–Lehmann median of all pairwise differences from placebo; omega-3-carboxylic acids = median of [omega-3-carboxylic acids % change—placebo % change] (Hodges–Lehmann estimate). HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides](https://figures.cochat.ai/paper-figures/e7eb67e0a6f348d0a96055fb267f6224/omega-3-fatty-acid-formulations-in-cardiovascular-disease-dietary-supplements-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although OM-3 dietary supplements are available, there are no Food and Drug Administration (FDA)-approved over-the-counter (OTC) OM-3 medications in the USA.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently available OM-3 products in the US are either prescription (Rx) medications or non-Rx OM-3 dietary supplements (e.g., fish oils) [7].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [7]
In the citing paper
“Patients and health care providers may mistakenly believe that dietary supplements are OTC medications [7].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“Some trials showed significant improvements in clinical outcomes [81, 86, 87], whereas others did not [88–91].”
ResultInflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 1×
“Some trials showed significant improvements in clinical outcomes [81, 86, 87], whereas others did not [88–91].”
ResultEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“More recently, clinical trials of ezetimibe (IMPROVE-IT [82]) and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (OSLER study [83] and ODYSSEY LONG TERM study [84]) have confirmed or suggested that statin add-on therapy may be effective in further reducing residual cardiovascular risk.”
Background(1999) · PubMed · Cited by 2,062
EICOSAPENTAENOIC ACID AND PREVENTION OF THROMBOSIS AND ATHEROSCLEROSIS?
DYERBERG, J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91505-2 · Cited by 1,688
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509 · cited 1×
“More recently, clinical trials of ezetimibe (IMPROVE-IT [82]) and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (OSLER study [83] and ODYSSEY LONG TERM study [84]) have confirmed or suggested that statin add-on therapy may be effective in further reducing residual cardiovascular risk.”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162 · cited 4×
“Omega-3 and omega-6 fatty acids are incorporated into membrane phospholipids, where they alter the physical properties of cellular membranes and serve as precursors for several classes of lipid mediators [7, 8].”
BackgroundInfluentialLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms
Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.935 · Cited by 950 · cited 2×
“AA is converted into eicosanoids that generally have pro-inflammatory or pro-thrombotic effects, whereas those derived from EPA typically have anti-inflammatory or anti-thrombotic effects [6, 9].”
Backgroundn–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“In two independent studies of large US and Danish cohorts, individuals with life-long low triglycerides due to mutations in the apolipoprotein C3 (APOC3) gene had approximately 40 % lower coronary heart disease (CHD) risk than individuals with normal APOC3 alleles [21, 22].”
BackgroundThe composition of the Eskimo food in north western Greenland.
Bang, H. O., Dyerberg, J., & Sinclair, H. M. (1980) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/33.12.2657 · Cited by 807
Thies, F., Garry, J. M., Yaqoob, P., Rerkasem, K., Williams, J., Shearman, C. P., Gallagher, P. J., Calder, P. C., & Grimble, R. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12468-3 · Cited by 739
Cancer Research: Some Forward Steps
(1965) · The Lancet · doi:10.1016/s0140-6736(65)92229-4 · Cited by 731
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91658-8 · Cited by 690
Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1986.tb07607.x · Cited by 603
Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
Adkins, Y., & Kelley, D. S. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.12.004 · Cited by 557 · cited 3×
“AA is converted into eicosanoids that generally have pro-inflammatory or pro-thrombotic effects, whereas those derived from EPA typically have anti-inflammatory or anti-thrombotic effects [6, 9].”
Backgroundn–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497 · cited 1×
“More recently, genetic studies have revealed that inactivating mutations in the gene encoding ANGPTL4 (a regulatory factor in triglyceride metabolism) are associated with lower triglyceride levels and lower risk of coronary artery disease [25, 26].”
BackgroundCoding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
QUARTAN MALARIAL NEPHROTIC SYNDROME
Hendrickse, R. G., Adeniyi, A., Edington, G. M., Glasgow, E. F., White, R. H. R., & Houba, V. (1972) · The Lancet · doi:10.1016/s0140-6736(72)91373-6 · Cited by 447
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385 · cited 1×
“Parameter COMBOS study [14, 48] (8 weeks) ANCHOR study [15] (12 weeks) ESPRIT study [16] (6 weeks)”
BackgroundStandards of Medical Care in Diabetes—2015: Summary of Revisions
(2015) · Diabetes Care · doi:10.2337/dc15-s003 · Cited by 382
Cardioprotective mechanism of omega-3 polyunsaturated fatty acids
Endo, J., & Arita, M. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.08.002 · Cited by 369 · cited 1×
“Omega-3 fatty acids, particularly EPA, have pleiotropic effects at multiple steps involved in atherosclerosis [27, 28].”
BackgroundEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., & Wiviott, S. D. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.004 · Cited by 360
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358 · cited 3×
“Icosapent ethyl data are from the MARINE (Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension) study (12 weeks) [12].”
BackgroundMethodGrundy, S. M. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 347
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342 · cited 2×
“However, the triglyceride-lowering efficacy of prescription omega-3 fatty acids has been shown to be dose-dependent [12, 13, 15, 16, 78].”
Backgroundα-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis
Pan, A., Chen, M., Chowdhury, R., Wu, J. H., Sun, Q., Campos, H., Mozaffarian, D., & Hu, F. B. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.044040 · Cited by 329
Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 327
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306 · cited 1×
“Omega-3-acid ethyl esters values are based on pooled data from two studies [10, 11] (6 and 16 weeks’ duration) as reported in the omega-3-acid ethyl esters prescribing information [48].”
MethodThe Nomenclature of Lipids: Recommendations, 1976
(1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11778.x · Cited by 299
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284 · cited 1×
“DHA may raise LDL-C, whereas EPA has a neutral effect or may slightly lower LDL-C [17, 18].”
BackgroundDietary sources of omega 3 fatty acids: public health risks and benefits
Tur, J. A., Bibiloni, M. M., Sureda, A., & Pons, A. (2012) · British Journal of Nutrition · doi:10.1017/s0007114512001456 · Cited by 283
Marckmann, P., & Grønbæk, M. (1999) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600832 · Cited by 277 · cited 1×
“Subsequent diet-based studies suggested that increased omega-3 fatty acid consumption reduced cardiovascular mortality in high-risk (but not lowrisk) individuals [4].”
BackgroundJacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263 · cited 2×
“DHA may raise LDL-C, whereas EPA has a neutral effect or may slightly lower LDL-C [17, 18].”
BackgroundCawood, A. L., Ding, R., Napper, F. L., Young, R. H., Williams, J. A., Ward, M. J. A., Gudmundsen, O., Vige, R., Payne, S. P. K., Ye, S., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.022 · Cited by 243
Omega-3 fatty acid supplementation and cardiovascular disease
Jump, D. B., Depner, C. M., & Tripathy, S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r027904 · Cited by 239 · cited 3×
“Omega-3 and omega-6 fatty acids are incorporated into membrane phospholipids, where they alter the physical properties of cellular membranes and serve as precursors for several classes of lipid mediators [7, 8].”
BackgroundFish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA
Albert, B. B., Derraik, J. G. B., Cameron-Smith, D., Hofman, P. L., Tumanov, S., Villas-Boas, S. G., Garg, M. L., & Cutfield, W. S. (2015) · Scientific Reports · doi:10.1038/srep07928 · Cited by 238 · cited 3×
“In product testing, only 8 % of fish oil supplements met all international recommendations for levels of oxidation markers, and the safety of these oxidation products has not been well investigated [68, 70].”
BackgroundKastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233 · cited 3×
“Omega-3-carboxylic acids data are from the EVOLVE (Epanova for Lowering Very High Triglycerides) study (12 weeks) [13].”
BackgroundMethodThe nomenclature of lipids (Recommendations 1976) IUPAC-IUB Commission on Biochemical Nomenclature
(1978) · Biochemical Journal · doi:10.1042/bj1710021 · Cited by 223
Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia.
Bunea, R., Farrah, K. E., & Deutsch, L. (2004) · PubMed · Cited by 206
Overview of omega-3 Fatty Acid therapies.
Bradberry, J. C., & Hilleman, D. E. (2013) · PubMed Central · Cited by 181
Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00301-3 · Cited by 179 · cited 1×
“Omega-3-acid ethyl esters values are based on pooled data from two studies [10, 11] (6 and 16 weeks’ duration) as reported in the omega-3-acid ethyl esters prescribing information [48].”
MethodBorow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175 · cited 1×
“Omega-3 fatty acids, particularly EPA, have pleiotropic effects at multiple steps involved in atherosclerosis [27, 28].”
BackgroundResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 172
Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies
Klingenberg, R., & Hansson, G. K. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp477 · Cited by 169
Dangardt, F., Osika, W., Chen, Y., Nilsson, U. A., Gan, L., Gronowitz, E., Strandvik, B., & Friberg, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.046 · Cited by 154
Mita, T., Watada, H., Ogihara, T., Nomiyama, T., Ogawa, O., Kinoshita, J., Shimizu, T., Hirose, T., Tanaka, Y., & Kawamori, R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.03.005 · Cited by 153
Hazards of Hindsight — Monitoring the Safety of Nutritional Supplements
Cohen, P. A. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1315559 · Cited by 149 · cited 1×
“Importantly, it has been suggested that physicians and patients cannot be assured that dietary supplements are safe without sweeping legal and regulatory changes [66].”
BackgroundBernstein, A. M., Ding, E. L., Willett, W. C., & Rimm, E. B. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.148973 · Cited by 148
Fish Oil for the Treatment of Cardiovascular Disease
Weitz, D., Weintraub, H., Fisher, E., & Schwartzbard, A. Z. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ea0de0 · Cited by 138
Gajos, G., Rostoff, P., Undas, A., & Piwowarska, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.080 · Cited by 133 · cited 1×
“platelet aggregation, suggesting the potential for limiting thrombus formation following plaque rupture [47].”
BackgroundNishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.025 · Cited by 133
Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
Jarcho, J. A., & Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1507041 · Cited by 131 · cited 1×
“These studies emphasize that ‘‘lower LDL-C is better,’’ and that more can be done for statintreated patients to address residual cardiovascular risk [85].”
BackgroundDetermination of lipid oxidation products in vegetable oils and marine omega-3 supplements
Lise Halvorsen, B., & Blomhoff, R. (2011) · Food & Nutrition Research · doi:10.3402/fnr.v55i0.5792 · Cited by 125 · cited 1×
“In product testing, only 8 % of fish oil supplements met all international recommendations for levels of oxidation markers, and the safety of these oxidation products has not been well investigated [68, 70].”
BackgroundMaki, K. C., Orloff, D. G., Nicholls, S. J., Dunbar, R. L., Roth, E. M., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.420 · Cited by 104 · cited 2×
“However, the triglyceride-lowering efficacy of prescription omega-3 fatty acids has been shown to be dose-dependent [12, 13, 15, 16, 78].”
BackgroundKleiner, A. C., Cladis, D. P., & Santerre, C. R. (2015) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6816 · Cited by 93
Are the health benefits of fish oils limited by products of oxidation?
Turner, R., McLean, C. H., & Silvers, K. M. (2006) · Nutrition Research Reviews · doi:10.1079/nrr2006117 · Cited by 93 · cited 2×
“dized lipids have the potential to increase the risk of atherosclerosis and thrombosis [73].”
BackgroundOffman, E., Marenco, T., Ferber, S., Johnson, J., Kling, D., Curcio, D., & Davidson, M. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50464 · Cited by 92
Quality analysis of commercial fish oil preparations
Ritter, J. C. S., Budge, S. M., & Jovica, F. (2013) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.5994 · Cited by 85 · cited 1×
“, lower EPA content and higher DHA content than stated on the label) [69].”
BackgroundTriglycerides on the rise: should we swap seats on the seesaw?
Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85
Jackowski, S. A., Alvi, A. Z., Mirajkar, A., Imani, Z., Gamalevych, Y., Shaikh, N. A., & Jackowski, G. (2015) · Journal of Nutritional Science · doi:10.1017/jns.2015.21 · Cited by 77 · cited 1×
“Testing of 171 Canadian omega-3 fatty acid dietary supplements revealed that 50 % of products failed at least one of the voluntary safety standards recommended for product oxidation [71].”
BackgroundTriglyceride-Rich Lipoproteins and Coronary Artery Disease Risk: New Insights From Human Genetics
Khetarpal, S. A., & Rader, D. J. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.305172 · Cited by 69 · cited 1×
“ApoC-III is a protein coded by the APOC3 gene that is part of the very-low-density lipoprotein complex and inhibits lipases, thus decreasing the uptake of triglyceride-rich lipoprotein particles [23].”
BackgroundSatoh-Asahara, N., Shimatsu, A., Sasaki, Y., Nakaoka, H., Himeno, A., Tochiya, M., Kono, S., Takaya, T., Ono, K., Wada, H., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0269 · Cited by 64 · cited 1×
“Atherosclerosis is a chronic inflammatory disease [36–38] and EPA may reduce the components of inflammation via beneficial effects on eicosanoids, as discussed earlier [6, 9], and by altering pro-inflammatory cytokine levels [39, 40].”
BackgroundEffects of fatty acids on endothelial cells: inflammation and monocyte adhesion
Grenon, S. M., Aguado-Zuniga, J., Hatton, J. P., Owens, C. D., Conte, M. S., & Hughes-Fulford, M. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.04.010 · Cited by 45
Tatsuno, I., Saito, Y., Kudou, K., & Ootake, J. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.01.006 · Cited by 42 · cited 1×
“However, the triglyceride-lowering efficacy of prescription omega-3 fatty acids has been shown to be dose-dependent [12, 13, 15, 16, 78].”
BackgroundIshida, T., Ohta, M., Nakakuki, M., Kami, H., Uchiyama, R., Kawano, H., Notsu, T., Imada, K., & Shimano, H. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.01.001 · Cited by 41 · cited 1×
“DHA on LDL-C may be attributed in part to findings that DHA may downregulate the LDL receptor [19, 20].”
BackgroundZargar, A., & Ito, M. K. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0004 · Cited by 39 · cited 1×
“issues discussed above, one further aspect hindering the therapeutic use of omega-3 fatty acid dietary supplements is that dietary supplements may require a high pill burden to achieve the dose levels found in prescription products, which in turn may adversely impact treatment adherence [74, 75].”
BackgroundToyama, K., Nishioka, T., Isshiki, A., Ando, T., Inoue, Y., Kirimura, M., Kamiyama, T., Sasaki, O., Ito, H., Maruyama, Y., et al. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6496-3 · Cited by 39 · cited 1×
“For example, EPA has beneficial effects on endothelial function [29, 30] by improving the balance between the vasodilator nitric oxide and damaging reactive oxygen species [31].”
BackgroundSasaki, J., Miwa, T., & Odawara, M. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej11-0394 · Cited by 31 · cited 1×
“For example, EPA has beneficial effects on endothelial function [29, 30] by improving the balance between the vasodilator nitric oxide and damaging reactive oxygen species [31].”
BackgroundModulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men
Dawson, K., Zhao, L., Adkins, Y., Vemuri, M., Rodriguez, R. L., Gregg, J. P., Kelley, D. S., & Hwang, D. H. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.004 · Cited by 24 · cited 1×
“DHA on LDL-C may be attributed in part to findings that DHA may downregulate the LDL receptor [19, 20].”
BackgroundOmega‐3 Fatty Acids and Total Polychlorinated Biphenyls in 26 Dietary Supplements
Shim, S. M., Santerre, C. R., Burgess, J. R., & Deardorff, D. C. (2003) · Journal of Food Science · doi:10.1111/j.1365-2621.2003.tb07042.x · Cited by 24
Ando, K., Watanabe, T., Daidoji, H., Otaki, Y., Hashimoto, N., Kumagai, Y., Hashimoto, N., Narumi, T., Kadowaki, S., Yamaura, G., et al. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.12007 · Cited by 16
Shintani, Y., & Kawasaki, T. (2012) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(12)61732-x · Cited by 13
Watanabe, T., Miyamoto, T., Miyasita, T., Shishido, T., Arimoto, T., Takahashi, H., Nishiyama, S., Hirono, O., Matsui, M., Sugawara, S., et al. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.12.008 · Cited by 12
Mason, R. P., Jacob, R. F., Corbalan, J. J., & Maliñski, T. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.074 · Cited by 12 · cited 1×
“For example, EPA has beneficial effects on endothelial function [29, 30] by improving the balance between the vasodilator nitric oxide and damaging reactive oxygen species [31].”
BackgroundWakita, Y., Wakida, Y., Itou, T., & Mizuno, R. (2011) · Circulation · doi:10.1161/circ.124.suppl_21.a8893 · Cited by 6
Nieman, K. M., Dicklin, M. R., Bell, M., Rains, T. M., & Maki, K. C. (2014) · The FASEB Journal · doi:10.1096/fasebj.28.1_supplement.1035.6 · Cited by 5 · cited 1×
“Also notable is the finding that higher baseline triglycerides were generally associated with greater triglyceride reductions [12, 18, 55].”
Background
Research works printed but not linked: 4
- Niki T Wakatsuki T Bando M Effects of additional eicosapentaenoic acid to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems [abstract 14434] Circulation. 2012 126 21 Suppl. 14434
- Katoh A Ikeda H Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese] Ther Res. 2011 32 6 863 868
- Truong P Johnson C Gabriel D Variability of cholesterol and saturated fat content in dietary supplements [abstract P72] Circulation. 2007 115 8 e238
- Lopez JAG Ito MK PLA chapter update: prescription fish oil and Blue Cross of Idaho LipidSpin. 2010 8 3 32 34
Cited by
Serhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 555
“It is clear that dietary supplements containing the n-3 fatty acids, precursors to the Rvs, PDs and MaRs, are not substitutes for prescription drugs (134).”
BackgroundSkulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Dietary Polyunsaturated Fatty Acids (PUFAs): Uses and Potential Health Benefits
Kapoor, B., Kapoor, D., Gautam, S., Singh, R., & Bhardwaj, S. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00363-3 · Cited by 418
A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids
Cholewski, M., Tomczykowa, M., & Tomczyk, M. (2018) · Nutrients · doi:10.3390/nu10111662 · Cited by 372
“This is due to the fact that the food of many fish are algae rich in EPA and DHA, and other organisms consuming algae, like fish or marine invertebrates [136,137].”
BackgroundInfluentialPPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
“Apparently, products containing DHA may increase LDL-C levels, whereas those containing EPA only products do not lead to a similar consequence [104,105].”
Background
Metadata
- Authors
- Fialkow, J.
- Affiliations
- Baptist Hospital of Miami (US)
- Corresponding author
- Fialkow, Jonathan
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2016-04-30
- Volume
- 16
- Issue
- 4
- Pages
- 229-239
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- PMC
- PMC4947114
- OpenAlex
- W2345135102
- Cited by
- 80
- References
- 89
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 5 · 2023: 20 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 6 · 2017: 6 · 2016: 1
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida) (submittedVersion)
- Funders
- Amarin Corporation
- Amarin Pharma
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- omega-3 fatty acids, icosapent ethyl, omega-3 acid ethyl esters, dietary supplements, fish oil, eicosapentaenoic acid, docosahexaenoic acid, LDL cholesterol, dyslipidemia, cardiovascular disease, FDA regulation of dietary supplements, oxidized fatty acids
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Chemistry, Pharmaceutical, Diet, Docosahexaenoic Acids, Humans, Cholesterol, LDL, Eicosapentaenoic Acid, Hypertriglyceridemia, Fatty Acids, Omega-3, Dietary Supplements, Dyslipidemias, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.